Pharmaceutical Cleanroom Sterile Compounding SWMS
Sterile compounding in ISO Class 5 / 7 cleanroom — gowning and airlock entry, biological safety cabinet / isolator work, parenteral fill-finish operations, environmental monitoring, single-pass airflow integrity, post-compounding decontamination.
SWMS variants reference your state’s WHS legislation. Instant download after payment.
Pharmaceutical cleanroom sterile compounding covers the preparation of sterile pharmaceutical products in an ISO Class 5 and Class 7 cleanroom — gowning and airlock entry, work in a biological safety cabinet or isolator, parenteral fill-finish operations, environmental monitoring, single-pass airflow integrity, and post-compounding decontamination. The work is not classified as High-Risk Construction Work, so this product sits at the non-HRCW price, but it carries genuine occupational hazards — exposure to potent or hazardous pharmaceutical compounds, ergonomic strain in the constrained cabinet posture, and the need to maintain both sterility and worker protection at once — that warrant a documented safe system of work.
Sterile compounding is governed by pharmaceutical manufacturing standards and the facility's quality framework, but from an occupational-health standpoint the controlling consideration is the dual goal of protecting the product from the operator and protecting the operator from the product. Where the compound is a cytotoxic or otherwise hazardous drug, the operator handles it in a containment cabinet or isolator with controls that go beyond sterility, and the airflow that keeps the product sterile must not blow hazardous aerosol back at the operator. The exposure controls follow the framework for managing hazardous chemicals and the guidance on handling hazardous medicines, with respiratory and skin protection and decontamination of the work area.
This SWMS is jurisdiction-neutral within Australia and written to the model WHS framework. Victoria operates under the Occupational Health and Safety Act 2004 and OHS Regulations 2017 — check the VIC-specific variant for the local equivalents of the duties and codes cited here.
Hazards identified
10 hazards covered, sorted by priority.
Acute and chronic health effects including reproductive harm and sensitisation from inhalation or skin contact with potent or cytotoxic compounds during compounding.
Inhalation or skin and eye exposure to a hazardous compound from an aerosol or splash generated during reconstitution, withdrawal, and filling.
Percutaneous injury and exposure to the compound, with infection or drug-exposure consequences, from needles and sharps used in fill-finish.
Operator exposure to a hazardous compound if the biological safety cabinet or isolator airflow is disrupted by poor technique or a failed unit.
Musculoskeletal strain to the neck, shoulders, and arms from prolonged work in the fixed, reaching posture required at a cabinet or isolator.
Sprain or fall on cleanroom flooring during cleaning or after a spill.
Heat discomfort and fatigue over a long shift in full gowning and a respirator where a hazardous compound is handled.
Operator and area contamination from a spill of a hazardous or cytotoxic compound requiring specific spill response.
Fatigue and stress affecting concentration over sustained precise work where an error has product and patient consequences.
Respiratory and skin irritation from the disinfectants and decontamination agents used to maintain the cleanroom and clean the cabinet.
Control measures
Hierarchy-of-controls order: elimination → substitution → isolation → engineering → administrative → PPE.
- 1Eliminate or substitute the most hazardous compounds where a less hazardous formulation or a closed-system transfer device can achieve the clinical purpose, and use closed-system transfer devices for hazardous-drug fill-finish to contain aerosol at source.
- 2Perform compounding of hazardous compounds in a containment biological safety cabinet or isolator designed to protect both the product and the operator, with airflow verified so hazardous aerosol is not directed at the operator.
- 3Maintain and verify the cabinet or isolator and the cleanroom airflow — single-pass airflow integrity, pressure cascades, and environmental monitoring — so containment and sterility are both assured before compounding.
- 4Use safe sharps-handling technique and safety-engineered sharps, with no recapping and sharps disposal at the point of use, to control needlestick and sharps injury.
- 5Train and assess operator technique for cabinet and isolator work so containment is not compromised by poor practice, and restrict compounding to assessed, competent operators.
- 6Apply ergonomic controls for the cabinet posture — adjustable seating, work-height optimisation, task rotation, and micro-breaks — to control musculoskeletal strain.
- 7Maintain a hazardous-drug spill response capability — a spill kit, a documented procedure, and trained operators — to contain and decontaminate a spill of a hazardous or cytotoxic compound.
- 8Manage heat and gowning discomfort with shift scheduling, breaks out of gowning, and hydration, balanced against the contamination-control requirements.
- 9Handle disinfectants and decontamination agents to their safety data sheets with ventilation and skin protection, and maintain footing controls during and after cleanroom cleaning.
- 10Provide a fatigue-management and support approach for sustained precision work, with rotation and breaks to maintain concentration.
- 11Provide PPE as the final layer — chemotherapy-rated gloves (double-gloved for hazardous drugs), gowns rated for the compound, respiratory and eye protection for hazardous handling, and the cleanroom garment — selected, fit-tested, and inspected before use.
- 12Verify aseptic-technique and hazardous-drug-handling competencies for every operator, and brief on the SWMS, the containment controls, and the spill response before compounding.
Applicable Codes of Practice
Becomes legally binding under Section 26A of the WHS Act from 1 July 2026. Governs the handling of hazardous and cytotoxic pharmaceutical compounds, including containment, exposure control, and spill response.
Becomes legally binding under Section 26A from 1 July 2026. Governs the ergonomic assessment and control of the sustained constrained posture required at a biological safety cabinet or isolator.
Safety in laboratories — Microbiological safety and containment. Informs the use and verification of biological safety cabinets and the containment practice for the cleanroom work.
Cleanrooms, workstations, safety cabinets and pharmaceutical isolators — methods of test. Provides the test methods that underpin verification of cabinet and isolator airflow and integrity.
Selection, use and maintenance of respiratory protective equipment. Drives the selection and fit-testing of respiratory protection where a hazardous or cytotoxic compound is handled.
Occupational protective gloves. Informs the selection of chemotherapy-rated and chemical-resistant gloves for handling hazardous compounds in the cleanroom.
Who this is for
- →Hospital and compounding pharmacies preparing sterile parenteral and cytotoxic products.
- →Compounding technicians and pharmacists working in ISO Class 5 and Class 7 cleanrooms.
- →Pharmaceutical manufacturers running aseptic fill-finish operations.
- →Pharmacy and pharmaceutical employers requiring a defensible occupational SWMS for cleanroom compounding.
- →Cleanroom environmental-monitoring and cleaning staff supporting sterile compounding.
What you receive
- ✓Editable Microsoft Word .docx — open in Word or Google Docs, drop in your company logo and ABN.
- ✓State-specific variant matched to the jurisdiction selected at checkout (NSW, VIC, QLD, SA, WA, TAS, NT, or ACT).
- ✓All 10 hazards risk-assessed with inherent and residual ratings against a documented control set.
- ✓Containment and exposure controls referenced to AS 2243.3, AS 1807, AS/NZS 1715, and the model codes.
- ✓An occupational-health focus that complements, rather than duplicates, the facility's pharmaceutical quality system.
- ✓CIH-reviewed content written to be defended in front of a site quality lead or a SafeWork inspector.
- ✓Instant download on payment, with a re-download window so you can retrieve the file again if needed.
- ✓Sign-on register and review-log structure ready for site-specific completion by the PCBU.
Worked example
A hospital pharmacy in Brisbane operates a sterile compounding cleanroom preparing chemotherapy infusions in an ISO Class 5 containment isolator within an ISO Class 7 room. Although the work is not High-Risk Construction Work, the pharmacy prepares an occupational SWMS to control the hazardous-drug exposure, ergonomic, and sharps risks alongside its pharmaceutical quality system, selecting the QLD variant. Compounders gown and enter through the airlock, and cytotoxic infusions are prepared in the containment isolator using closed-system transfer devices that contain aerosol at source. The isolator airflow and the room pressure cascades are verified before compounding so that containment and sterility are both assured and hazardous aerosol is not directed at the operator. Safety-engineered sharps are used with no recapping, and sharps are disposed of at the point of use. The constrained isolator posture is managed with adjustable seating, task rotation, and micro-breaks. A hazardous-drug spill kit and a trained spill response are in place. Operators wear double chemotherapy-rated gloves, a compound-rated gown, and respiratory protection appropriate to the drug. At the end of the session the isolator and work area are decontaminated to the documented procedure. The compounding session is completed without an exposure or sharps incident, and the signed SWMS, environmental-monitoring records, and competency assessments are retained alongside the batch documentation for the pharmacy's quality and work-health-and-safety files.
Related legislation
- Work Health and Safety Act 2011 (NSW) — Sections 19 (primary duty of care), 28 (worker duties), 46-49 (consultation)
- Work Health and Safety Regulation 2017 (NSW) — Sections 328-394 (hazardous chemicals), 39-43 (hazardous manual tasks framework)
- AS 2243.3:2022 — Safety in laboratories, Part 3: Microbiological safety and containment
- AS 1807 series — Cleanrooms, workstations, safety cabinets and pharmaceutical isolators — methods of test
- AS/NZS 1715:2009 — Selection, use and maintenance of respiratory protective equipment
Frequently asked questions
Why is sterile compounding not High-Risk Construction Work?
Sterile compounding does not meet any of the Reg 291 HRCW triggers — it is not construction work, confined-space entry, work at height, or the other defined categories. That is why this product sits at the $149 non-HRCW price and does not include a Reg 291 breakdown. It still carries genuine occupational hazards — hazardous-drug exposure, sharps, and ergonomic strain — so a documented safe system of work is appropriate.
How does the SWMS protect the operator as well as the product?
Sterile compounding has a dual goal — protecting the product from the operator and the operator from the product. The SWMS focuses on the operator-protection side, requiring containment isolators or biological safety cabinets with verified airflow, closed-system transfer devices for hazardous drugs, and PPE rated for the compound, so the airflow that keeps the product sterile does not blow hazardous aerosol back at the operator.
Does this duplicate our pharmaceutical quality system?
No. The SWMS complements the quality system rather than duplicating it. The quality system governs product sterility and manufacturing standards; the SWMS governs the occupational-health controls — hazardous-drug exposure, sharps, ergonomics, and spill response — that protect the worker. The two are designed to sit alongside each other in the site's documentation.
What controls apply when compounding cytotoxic drugs?
Cytotoxic and other hazardous drugs are handled in a containment isolator or biological safety cabinet with closed-system transfer devices, double chemotherapy-rated gloves, a compound-rated gown, and respiratory protection, with a hazardous-drug spill kit and trained spill response available. The SWMS treats hazardous-drug exposure as the leading hazard and applies the hierarchy from elimination and substitution through to PPE.
How is the ergonomic strain of cabinet work addressed?
Prolonged work in the fixed, reaching posture at a cabinet or isolator strains the neck, shoulders, and arms. The SWMS applies ergonomic controls under the hazardous-manual-tasks framework — adjustable seating, work-height optimisation, task rotation, and micro-breaks — because the constrained posture is a recognised musculoskeletal hazard in compounding work.